Table 1.
Description of patients subjected to therapeutic plasma exchange
| Pt No. | Age, years | Sex | Etiology | TRAb | Drugs administered during TPE (daily dose) | Indication | TPEs, n | fT3 before TPE, pmol/L | fT4 before TPE, pmol/L | fT3 after TPE, pmol/L | fT4 after TPE, pmol/L | Outcome after TPE |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 30 | F | GD | 41 | Corticosteroids (60 mg), benzylthiouracil (75 mg) | Inefficiency before surgery for exophthalmus | 1 | 15.0 | 57.0 | 7.0 | 38.7 | Thyroidectomy |
| 2 | 66 | M | AIT | n.a. | Corticosteroids (50 mg), cholestyramine (12 g), PTU(350 mg) | Inefficiency with cardiac arrythmia and ischemic heart failure | 2 | 6.6 | 46.2 | 5.6 | 31.3 | Thyroidectomy |
| 3 | 51 | F | GD | 14 | Corticosteroids (60 mg) | CI due to agranulocytosis to ATD | 2 | 13.0 | 38.6 | 30.7 | Thyroidectomy | |
| 4 | 34 | F | GD | 23.6 | Corticosteroids (50 mg) | CI due to hepatotoxicity to ATD | 2 | 45.8 | 100.0 | 13.0 | 29.1 | Thyroidectomy |
| 5 | 48 | F | GD | 10.3 | Corticosteroids (60 mg) | CI due to agranulocytosis and hepatotoxicity to ATD | 2 | 14.9 | 60.9 | 5.4 | 24.4 | Thyroidectomy |
| 6 | 19 | F | GD | 41 | Corticosteroids (80 mg), cholestyramine (12 g) | CI due to agranulocytosis to ATD | 2 | 25.1 | 30.7 | 10.5 | 18.2 | Thyroidectomy |
| 7 | 22 | F | GD | 37.7 | Corticosteroids (40 mg), cholestyramine (12 g), Carbimazole (80 mg) | Inefficiency with <80 mg of Carbimazole | 2 | 10.9 | 40.7 | 6.0 | 24.4 | Medical follow-up |
| 8 | 55 | F | AIT | neg | Corticosteroids (60 mg), cholestyramine (120 mg), PTU(300 mg) | CI due to hepatotoxicity to ATD | 3 | 14.3 | 100.0 | 19.0 | 100.0 | Death |
| 9 | 31 | M | GD | 9.1 | Carbimazole (60 mg) | Inefficiency with cardiothyreosis and global heart failure | 3 | 100.0 | 14.8 | 41.4 | Radioactive iodine | |
| 10 | 34 | M | GD | n.a. | Corticosteroids (80 mg), thiamazol | CI due to hepatotoxicity to ATD | 3 | 11.6 | 55.3 | 15.3 | Thyroidectomy | |
| 11 | 78 | M | AIT | 0 | PTU (300 mg) | Inefficiency | 3 | 20.6 | 97.0 | 6.5 | 54.0 | Medical follow-up |
| 12 | 46 | M | GD | 10 | Corticosteroids (60 mg), cholestyramine (12 g) | CI due to agranulocytosis to ATD | 4 | 29.3 | 61.1 | 5.1 | 18.0 | Thyroidectomy |
| 13 | 42 | F | AIT | 0 | Corticosteroids (60 mg), cholestyramine (4 g), Carbimazole (60 mg) | Inefficiency with severe arrythmia | 4 | 8.6 | 46.5 | 3.4 | 26.4 | Thyroidectomy |
| 14 | 85 | M | AIT | 0 | Corticosteroids (50 mg), cholestyramine (12 g), PTU (300 mg) | Inefficiency with cardiac arrythmia and ischemic heart failure | 5 | 29.8 | >100.0 | 11.2 | 54.3 | Medical follow-up |
| 15 | 34 | F | GD | 39.3 | Corticosteroids (40 mg), PTU (500 mg) | CI due to agranulocytosis to ATD | 5 | 36.4 | 100.0 | 20.4 | 30.6 | Thyroidectomy |
| 16 | 54 | M | AIT | 0 | Corticosteroids (50 mg), cholestyramine (12 g), PTU (450 mg) | CI due to agranulocytosis to ATD | 5 | 16.4 | >100.0 | 11.3 | 75.6 | Thyroidectomy |
| 17 | 57 | M | GD | 13.4 | Corticosteroids (50 mg), cholestyramine (12 g), PTU (450 mg) | CI due thrombopenia to ATD | 5 | 21.4 | 55.5 | 10.4 | 33.5 | Thyroidectomy |
| 18 | 56 | M | toxic goiterO | Corticosteroids (60 mg), cholestyramine (8 g) | Inefficiency | 6 | 10.0 | 100.0 | 9.5 | 61.5 | Thyroidectomy | |
| 19 | 39 | F | activating mutation | n.a. | Cholestyramine (4 g), PTU (450 mg) | Inefficiency during pregnancy | 6 | 13.0 | 51.5 | 7.5 | 21.3 | Medical follow-up |
| 20 | 51 | F | GD | 40 | Corticosteroids (40mg), cholestyramine (12 g), PTU(300 mg) | CI due to agranulocytosis to ATD | 6 | 43.5 | 65.8 | 15.0 | 40.9 | Thyroidectomy |
| 21 | 69 | M | AIT | n.a. | Corticosteroids (60 mg), cholestyramine (12 g), PTU (450mg) | CI due to hepatotoxicity to ATD | 10 | 7.2 | 61.0 | 3.9 | 15.2 | Thyroidectomy |
| 22 | 16 | F | GD | 17 | Corticosteroids (30 mg), cholestyramine (12 g), PTU (600 mg) | CI due to cutaneous toxidermia to ATD | 10 | 48.2 | 100.0 | 18.0 | 28.5 | Thyroidectomy |
Pt, patient; PTU, propylthiouracil; fT4, free thyroxine; fT3, free tri-iodothyronine; TSH, thyroid-stimulating hormone; TPE, therapeutic plasma exchange; GD, Graves' disease; AIT, amiodarone-induced thyrotoxicosis; ATD, antithyroid drugs; TRAb, TSH receptor antibodies; CI, contraindication; n.a., not available; neg, negative.